Literature DB >> 10447959

N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase.

H Huang1, P Martasek, L J Roman, B S Masters, R B Silverman.   

Abstract

Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high as 1800-fold (Silverman, R. B.; Huang, H.; Marletta, M. A.; Martasek, P. J. Med. Chem. 1997, 40, 2813-2817). Here a library of 152 dipeptide amides containing nitroarginine and amino acids other than Phe are synthesized and screened for activity. Excellent inhibitory potency and selectivity for nNOS over eNOS and iNOS is achieved with the dipeptide amides containing a basic amine side chain (20-24), which indicates a possible electrostatic (or hydrogen bonding) interaction at the enzyme active site. The most potent nNOS inhibitor among these compounds is L-Arg(NO)()2-L-Dbu-NH(2) (23) (K(i) = 130 nM), which also exhibits the highest selectivity over eNOS (>1500-fold) with a 192-fold selectivity over iNOS. These compounds do not exhibit time-dependent inhibition. The order and the chirality of the amino acids in the dipeptide amides have profound influences on the inhibitory potency as well as on the isoform selectivity. These dipeptide amide inhibitors open the door to the design of potent and highly selective inhibitors of nNOS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447959     DOI: 10.1021/jm990111c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model.

Authors:  Silvia L Delker; Haitao Ji; Huiying Li; Joumana Jamal; Jianguo Fang; Fengtian Xue; Richard B Silverman; Thomas L Poulos
Journal:  J Am Chem Soc       Date:  2010-04-21       Impact factor: 15.419

2.  Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors.

Authors:  Jotaro Igarashi; Huiying Li; Joumana Jamal; Haitao Ji; Jianguo Fang; Graham R Lawton; Richard B Silverman; Thomas L Poulos
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

3.  Selective inhibition of human inducible nitric oxide synthase by S-alkyl-L-isothiocitrulline-containing dipeptides.

Authors:  J M Park; T Higuchi; K Kikuchi; Y Urano; H Hori; T Nishino; J Aoki; K Inoue; T Nagano
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Decreased production of neuronal NOS-derived hydrogen peroxide contributes to endothelial dysfunction in atherosclerosis.

Authors:  L S A Capettini; S F Cortes; J F Silva; J I Alvarez-Leite; V S Lemos
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 5.  Nitric oxide synthase and structure-based inhibitor design.

Authors:  Thomas L Poulos; Huiying Li
Journal:  Nitric Oxide       Date:  2016-11-23       Impact factor: 4.427

6.  Modulation of the myogenic response in renal blood flow autoregulation by NO depends on endothelial nitric oxide synthase (eNOS), but not neuronal or inducible NOS.

Authors:  Marcel Dautzenberg; Gerburg Keilhoff; Armin Just
Journal:  J Physiol       Date:  2011-08-08       Impact factor: 5.182

7.  Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors.

Authors:  Haitao Ji; José A Gómez-Vidal; Pavel Martasek; Linda J Roman; Richard B Silverman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  Nitric oxide synthases activation and inhibition by metallacarborane-cluster-based isoform-specific affectors.

Authors:  Robert Kaplánek; Pavel Martásek; Bohumír Grüner; Satya Panda; Jakub Rak; Bettie Sue Siler Masters; Vladimír Král; Linda J Roman
Journal:  J Med Chem       Date:  2012-11-01       Impact factor: 7.446

Review 10.  Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.

Authors:  Paramita Mukherjee; Maris A Cinelli; Soosung Kang; Richard B Silverman
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.